研究生学术报告预告登记(开题、中期、答辩)

       为加强研究生学术交流活动,推进学术创新,特开通“研究生学术报告预告区”。我校研究生和教师可以在预告区及时发布和了解有关研究生学术报告的信息,届时参加。也可就某学术报告展开专题讨论与交流。

报告人: 张伟三
学号: 1214213012
学院: 药物科学与技术学院
报告类型: 其他学术报告
日期: 3 November 2016
时间: 9:30 AM
地点: 24楼408
导师: 高文远
题目: The meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer
内容提要:

Lung cancer is the leading cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for most lung cancer and carries a 5-year survival rate of 15%. The squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common types of NSCLC. The data on long term use of hyperfractionated radiotherapy (HRT) in NSCLC treatment is lacking. We performed a meta-analysis, based on published randomized trials to compare HRT [continuous hyperfractionated accelerated radiotherapy (CHART)/continuous hyperfractionated accelerated radiotherapy weekend less (CHARTWEL)] vs. conventional fractionated (CF) radiotherapy in the treatment of NSCLC. A systematic search through the bibliographic databases, PubMed, Google Scholar and Cochrane Library was performed till December 2013. Of 63 studies identified, 3 studies were analyzed. All were randomized studies and included 1,005 patients in total. The pooled results of the studies showed that HRT did not improve overall survival (OS) of patients suffering from NSCLC compared to CF after 2 years (OR, 1.29; 95% CI, 0.98-1.71; P=0.16) and 3 years (OR, 0.55; 95% CI, 0.34-0.87; P=0.22) which was statistically significant. HRT was no better than CF in controlling tumour (OR, 1.40; 95% CI, 1.03-1.91). No significant difference in metastasis free survival (OR, 1.08; 95% CI, 0.83-1.39) and late dysphagia (OR, 1.48; 95% CI, 0.75-2.92) were observed between the two groups. The results of the present meta-analysis showed that HRT was not significantly better to conventional radiotherapy in NSCLC treatment.

图片:
登记人: 张伟三
登记时间: Wednesday, 11 October 2017, 3:17 PM